Skip to content

To Study Efficacy Of Brihat Manjisthadi Kshirbasti And Kwatha In The Manangement Of Vrikkamaya With Special Reference To Renal Failure

A Comparative Clinical Evaluation Of Brihat Manjisthadi Kshir-basti And Kwatha In The Management Of Vrikkamaya With Special Reference To Renal Failure - An Open Labeled Randomized Controlled Clinical Trail

Status
Active, not recruiting
Phases
Unknown
Study type
Interventional
Source
CTRI
Registry ID
CTRI/2022/07/043729
Enrollment
45
Registered
2022-07-05
Start date
Unknown
Completion date
Unknown
Last updated
2024-03-04

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Health Condition 1: N189- Chronic kidney disease, unspecified Health Condition 2: N189- Chronic kidney disease, unspecified

Interventions

None listed

Sponsors

Government Akhandanand Ayurveda College
Lead Sponsor

Eligibility

Inclusion criteria

Inclusion criteria: 1.Patients having confirm diagnosis of renal failure due to varied etiology for last 6- month duration 2.Patient has past history of overuse of NSIADs 3.Patients with GFR level 3 months) 4.Patients have creatinine value >1.5 mg/dl

Exclusion criteria

Exclusion criteria: 1.Patients having age 60 yrs 2.AIDS 3.Diabetic nephropathy 4.Patient of hepato-renal insufficiency or renal insufficiency due to hemodynamic circulatory disorder and CCF 5.History of kidney transplant 6.Serious acute organic disease 7.Neoplasm of kidney 8.Female patient having risky pregnancy 9.Uncontrolled arrhythmia or severe cardiac disease 10.(In Basti group patients) Anal pathology like big piles, Fistula, Fissure 11.Associated with any other serious systemic disease or complications, which leads to fatal complications will be excluded

Design outcomes

Primary

MeasureTime frame
It is expected that the trail drugs will break the pathogenesis of renal failure and thus will be effective in the management of Renal failure.Timepoint: Patient will be advised to admit in the hospital as kshir-basti will be given daily for 30 days. After treatment patient will be advised to visit the hospital once per week for 4 weeks as follow up.

Secondary

MeasureTime frame
It is expected that proposed herbal formulation will detoxify the body, restoring the normal function of vital organs especially in liver, kidney and digestion. Kshir-basti (that is a type of Yapana basti) administration will also act on same line along with the implantation of the properties of best jeevaniya dravya milk.Timepoint: Patient will be advised to admit in the hospital as kshir-basti will be given daily for 30 days. After treatment patient will be advised to visit the hospital once per week for 4 weeks as follow up.

Countries

India

Contacts

Public ContactDr Surendra Soni

Government Akhandanand Ayurveda College and Hospital

surendraasoni@gmail.com9408441150

Outcome results

None listed

Source: CTRI (via WHO ICTRP) · Data processed: Feb 4, 2026